Diffusion Pharmaceuticals (NASDAQ:DFFN) Shares Down 0.4%
Diffusion Pharmaceuticals (NASDAQ:DFFN) Shares Down 0.4%
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) shares dropped 0.4% during mid-day trading on Tuesday . The stock traded as low as $6.26 and last traded at $6.34. Approximately 3,125 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 45,431 shares. The stock had previously closed at $6.36.
Wall Street Analysts Forecast Growth
DFFN has been the subject of several recent research reports. HC Wainwright upgraded Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price target for the company in a research note on Tuesday, August 16th. StockNews.com upgraded Diffusion Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, August 15th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Trading Down 0.2 %
The company has a 50 day moving average of $7.06 and a 200-day moving average of $11.67. The firm has a market capitalization of $12.90 million, a P/E ratio of -0.51 and a beta of 1.53.
Hedge Funds Weigh In On Diffusion Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DFFN. JPMorgan Chase & Co. acquired a new position in Diffusion Pharmaceuticals in the 1st quarter valued at $106,000. Renaissance Technologies LLC raised its holdings in Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock valued at $331,000 after acquiring an additional 101,100 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Diffusion Pharmaceuticals in the 2nd quarter valued at $71,000. 10.25% of the stock is owned by institutional investors and hedge funds.Diffusion Pharmaceuticals Company Profile
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Featured Articles
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- GameStop Stock Just Flashed A Buy Signal
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
週二午盤,納斯達克的股價下跌了0.4%。該股一度跌至6.26美元,最後報6.34美元。午盤交易中,約有3,125股股票成交,較45,431股的日均成交量下降了93%。該股此前收盤價為6.36美元。
華爾街分析師預測經濟增長
DFFN是最近幾份研究報告的主題。在8月16日週二的一份研究報告中,HC Wainwright將Diffation PharmPharmticals的評級從中性上調至買入,並為該公司設定了9.50美元的目標價。在8月15日(星期一)的一份研究報告中,StockNews.com將擴散製藥公司的評級從“賣出”上調為“持有”。
到達擴散製藥公司警報:擴散製藥公司股價下跌0.2%
該公司的50日移動均線切入位在7.06美元,200日移動均線切入位在11.67美元。該公司的市值為1,290萬美元,本益比為-0.51,貝塔係數為1.53。
對沖基金對擴散製藥的看法
幾家對沖基金和其他機構投資者最近增持或減持了DFFN的股份。今年第一季度,摩根大通以10.6萬美元的價格購入了擴散製藥公司的一個新頭寸。復興科技有限責任公司在第一季度增持了8.3%的擴散製藥股份。復興科技有限責任公司在上個季度增持了101,100股後,現在擁有1,324,202股該公司股票,價值331,000美元。最後,Trexquant Investment LP在第二季度收購了擴散製藥公司的一個新頭寸,價值7.1萬美元。10.25%的股票由機構投資者和對沖基金持有。擴散製藥公司簡介
(獲取評級)
擴散製藥公司是一家生物製藥公司,該公司開發新的療法,以增強人體輸送氧氣的能力。它的主要候選產品是反式番茄酸鈉,開發這種藥物是為了促進氧氣向組織的擴散,以及治療新冠肺炎病。擴散製藥公司成立於2001年,總部設在弗吉尼亞州夏洛茨維爾。
專題文章
- 免費獲取StockNews.com關於擴散藥物的研究報告(DFFN)
- Enphase Energy有沒有能力繼續往上沖?
- 獨一無二的氫燃料電池庫存
- 這兩只被低估的股票已經做好了進一步沖高的準備
- 化工和化肥庫存中是否隱藏著寶藏?
- GameStop股票剛剛閃爍了買入信號
獲得《擴散醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對擴散製藥及相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧